The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).
 
Ignacio Matos Garcia
No Relationships to Disclose
 
Enrique Grande
Research Funding - Astellas Oncology (Inst); AstraZeneca Spain (Inst); Pfizer (Inst)
 
Rocio Garcia-Carbonero
Honoraria - Amgen (I); Boehringer Ingelheim (I); Lilly (I); Merck (I); Novartis (I); Pfizer (I); Roche (I)
Consulting or Advisory Role - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb (I); Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Pfizer (I); Roche (I)
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim (I); Ipsen; Lilly (I); Merck; Novartis; Pfizer; Pfizer (I); Roche; Roche (I); Sanofi
 
Carlos Lopez
Consulting or Advisory Role - Bayer; Eisai; MSD Oncology; Novartis; Pfizer
Research Funding - Bayer; Eisai; MSD Oncology; Novartis; Pfizer
 
Alexandre Teule
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Novartis
 
Jaume Capdevila
No Relationships to Disclose